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A B S T R A C T
 
Background: Infectious complications represent the main cause of morbidity and mortality 
in chronic lymphocytic leukemia. It has been reported that polymorphisms of the mannose-
binding lectin 2 (MBL2) genes are correlated with MBL protein serum levels and, consequently, 
are associated with the development of infectious diseases.
Objective: The purpose of this study was to investigate the possible association between 
MBL2 gene polymorphisms and risk of infection in chronic lymphocytic leukemia patients.
Methods: Peripheral blood samples from 116 chronic lymphocytic leukemia patients were 
collected; after genomic DNA extraction, real time polymerase chain reaction was used to 
determine the polymorphisms of the promoter region and exon 1 of the MBL2 gene.
Results: A high frequency of Binet stage A (p-value = 0.005) and absence of splenomegaly 
(p-value = 0.002) were observed in patients with no infection; however, variant alleles/
genotypes and haplotypes of this gene had no impact on the risk of infection.
Conclusion: To the authors’ knowledge, this is the first study describing the association 
between MBL2 polymorphisms and infectious disease in chronic lymphocytic leukemia. 
Although it was not possible to demonstrate any influence of MBL2 polymorphisms as a 
genetic modulator of infection in chronic lymphocytic leukemia, the authors believe that 
the present data are clinically relevant and provide the basis for future studies.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. 
All rights reserved. 
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the 
progressive accumulation of mature B cells in the peripheral 
blood, bone marrow, and lymphoid tissues; it is the most 
common adult leukemia in the Western world.1 CLL patients 
present a highly variable clinical course, with overall survival 
ranging from months to decades.2 Risk stratification based 
on clinical and laboratory features (lymphadenopathy, 
organomegaly, and cytopenia)3,4 has been used to establish 
prognostic risk groups. Additionally, several disease-related 
markers have been described as potential prognostic factors, 
including cytogenetic abnormalities,5 mutational status of the 
variable region of immunoglobulin heavy chain genes (IgVH),6 
and ZAP-70.7
Despite the relatively good prognosis, infectious 
complications are the main cause of morbidity and mortality 
in CLL.8 It has been estimated that up to 50% of patients 
suffer from recurrent infections, especially involving 
mucous membranes.9 The pathogenesis of infection in 
CLL is multifactorial; hypogammaglobulinemia is the most 
recognized inherent immune defect in CLL patients, but cell-
mediated immunity10 and complement activity have been 
correlated to the immunodeficiency status.11
Genetic variation of innate immunity components may 
influence infection susceptibility.12 The mannose-binding lectin 
2 (MBL2) gene is a member of the innate immune system, and 
the encoded protein (MBL2) plays an important role in the 
identification of pathogens as a pattern recognition molecule, 
since it is able to activate the complement system.13 It has been 
reported that single nucleotide polymorphisms (SNPs) located 
within the promoter region and exon 1 of the MBL2 gene are 
correlated with MBL protein serum levels and, consequently, 
associated to a higher risk for the development of infectious 
disease. Three common polymorphisms in the structural 
gene-coding region are found at codons: 52 (D variant), 54 (B 
variant), and 57 (C variant), which are collectively denoted by 
‘O’, while the wild-type variant is termed ‘A’. Additionally, 
two relevant SNPs in the promoter region at positions -550 
(H/L) and -220 (X/Y) have been identified as regulators of 
protein expression.14 The combinatorial effect of SNPs in 
the promoter region and exon 1 of the MBL2 gene results in 
different haplotypes and variations in functional MBL protein 
concentrations.15 Haplotypes harboring Y and A alleles are 
associated with high or normal serum levels of MBL protein, 
while X and O (B, C, or D) alleles are associated with lower 
levels.16 The H/L variants have minimal influence on MBL 
concentrations. The expression pattern of the MBL protein in 
serum, according to the haplotypes, is established as: HYA > 
LYA > LXA >> HYD = LYB = LYC.17,18
The present study aimed to investigate the frequency of 
variant alleles/genotypes of the promoter region and exon 1 
of the MBL2 gene in CLL and to correlate these polymorphisms 




Peripheral blood samples from 116 CLL patients were collected 
at the Fundação de Hematologia e Hemoterapia de Pernambuco 
(HEMOPE). The diagnosis of CLL was based on morphology and 
the Matutes immunophenotypic analysis system.19 Clinical 
and epidemiological data (including occurrence of infections) 
were obtained through the medical records. All clinical findings 
were confirmed with laboratory tests, including complete blood 
counts, chest radiography, and fluid cultures (from blood and 
urine). This study was approved by the local Research Ethics 
Committee (#036/2011) and, in accordance with the Declaration 
of Helsinki, informed consent was obtained from all patients.
MBL2 genotyping
After genomic DNA extraction, real time polymerase chain 
reaction was used to determine the polymorphisms of the 
promoter region and exon 1 of the MBL2 gene using a Rotor 
Gene 6000™ apparatus (Corbett Research Mortlake - Sydney, 
Australia). The promoter region of the MBL2 gene was 
genotyped by the TaqMan® system (Applied Biosystems 
- Foster City, CA, USA) using specific probes. The following 
primers and probes were used to determine H/L alleles 
(-550): 5’-CCAACGTAGTAAGAAATTTCCAGAGA-3’ forward, 
5’-CAACCCAGCCCAGAATTAACTG-3’ reverse, 5’FAM-
AGCCTGTGTAAAAC-MGB-3’, and 5’VIC-CCTGTCTAAAACACC-
MGB-3’. For the X/Y alleles (-220), the following primes 
and probes were used: 5’-GCACGGTCCCATTTGTTCTCA-3’ 
forward, 5’-GCGTTGCTGCTGGAAGACTATAAA-3’ reverse, 
5 ’VIC-CATGCTTTCGGTGGCAG-MGB-3’ ,  and 5’FAM-
CATGCTTTCCGTGGCAG-MGB-3’. Protocol conditions are 
available on the SNP500-Cancer website.20
Genotyping of the exon 1 of the MBL2 gene was performed 
using SYBR Green® fluorophore (Applied Biosystems 
- Foster City, CA, USA) with the following primers: 
forward 5’-AGGCATCAACGGCTTCCCA-3’ and reverse 
5’-CAGAACAGCCCAACACGTACCT-3’. Melting curve profiles 
were obtained using the dissociation software of the Rotor 
Gene 6000™. The three allelic variants of exon 1 were grouped 
as allele ‘O’, whereas the wild-type allele was termed ‘A’. The 
haplotypes of the MBL2 gene were grouped into two groups 
according to MBL production levels: high (HYA and LYA) and 
intermediate/low levels (LXA, HYO, and LYO), as previously 
described.21
Statistical analysis
In order to analyze MBL2 polymorphisms and infectious events, 
the patients were divided into two groups according to the 
presence or absence of infection. Clinical and laboratory 
features were then compared. Fisher’s exact test was employed 
to compare differences between categorical variables, and 
Student’s unpaired t-test was used to compare continuous 
variables. The follow-up time was established as the time 
of interval from diagnosis until the analysis of the patient’s 
health record. The haplotype frequencies were calculated 
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using Arlequim software version 3.1 (Geneva University - 
Geneva, Switzerland). Allele and genotype frequencies and 
the statistical analyses were performed using SPSS version 
19.0 (IBM Corporation - Somers, NY, USA), with the level of 
significance set at 5%.
Results
The main clinical and laboratory features are summarized in 
Table 1. Infectious events were recorded in 44 (38%) of the 116 
patients analyzed. Respiratory tract infections (n = 19; 43%) 
and herpes viruses (n = 8; 18%) were the most frequent cases 
of infection. Patients with no infectious events presented a 
follow-up time significantly lower than those with infections 
(p-value = 0.034). Regarding the Binet staging system, a higher 
frequency of stage A was observed in patients with no infection 
(p-value = 0.005). The development of splenomegaly (mainly 
due to lymphoid infiltration) was significantly associated with 
infectious events (p-value = 0.002). Lymphadenomegaly was 
the most common form of impairment (n = 52; 45%) in the 
present cohort, but no difference between patients with and 
without infection was observed (p-value = 0.1).
The genotype distributions were in agreement with Hardy-
Weinberg equilibrium. For the group of patients with no 
infection, the -221 allele frequencies were 0.18 (allele X) and 
0.82 (allele Y), and the -550 allele frequencies were 0.34 (allele 
H) and 0.66 (allele L); the frequencies of the A and O alleles 
of exon 1 were 0.76 and 0.24, respectively. In the group of 
patients with infections, the frequencies were: 0.21 (X), 0.79 
Characteristics of CLL patients Total (n = 116) No infection (n = 72) Infection (n = 44) p-valueb 
Gender - n (%) 0.91
    Male 64 (55.2) 40 (55.6) 24 (54.5)
    Female 52 (44.8) 32 (44.4) 20 (45.5)
Agea - years 65.5 (32.3 - 105.7) 65.6 (32.3 - 105) 65.5 (37.3 - 97.3) 0.95
Follow-upa - years 4 (1 - 20) 3.5 (1 - 20) 5 (1 -14) 0.034c
WBCa x 10³/mm³ 75 (4.6 - 556) 71.5 (6.1 - 556) 81.4 (79 - 361.9) 0.5
Hemoglobina - g/dL 11.8 (4.2 - 16.4) 11.9 (4.2 - 16.2) 11.7 (5.3 - 16.4) 0.74
Plateletsa × 10³/mm³ 181.6 (16.9 - 374) 180.7 (16.9 - 374) 183.1 (79 - 361.9) 0.86
Lymphocytesa × 10³/mm³ 65.1 (2.8 - 545) 61.5 (3.9 - 54.5) 71 (2.8 - 260.3) 0.49
Neutrophilsa × 10³/mm³ 6.9 (0.5-30.9) 7 (0.7 - 30.9) 6.8 (0.5 - 22.9) 0.77
LDHa - IU/L 423.2 (135 - 1522) 409.2 (138 - 1522) 446.4 (135 - 910) 0.4
CD19a - n (%) 78.3 (31 - 99) 78.1 (31 - 99) 78.8 (45 - 97) 0.86
CD38 - n (%) 0.1
    Positive 35 (30.2) 20 (27.8) 15 (34.1)
    Negative 72 (62) 49 (68. 1) 23 (52.3)
    Missing 9 (7.8) 3 (4.1) 6 (13.6)
Binet stage - n (%) 0.005c
    A 52 (44.8) 41 (56.9) 11 (25)
    B 29 (25) 12 (16.7) 17 (38.7)
    C 22 (19) 12 (16.7) 10 (22.7)
    Missing 13 (11.2) 7 (9.7) 6 (13.6)
Hepatomegaly - n (%) 0.17
    Present 17 (14.7) 8 (11.1) 9 (20.5)
    Absent 99 (85.3) 64 (89.6) 35 (79.5)
Splenomegaly - n (%) 0.002c
    Present 38 (32.8) 16 (22.2) 22 (50)
    Absent 78 (67.2) 56 (77.8) 22 (50)
Lymphadenomegaly - n (%) 0.1
    Present 52 (44.8) 28 (38.9) 24 (54.5)
    Absent 64 (55.2) 44 (61.1) 20 (45.5)
WBC: white blood cell; LDH: lactate dehydrogenase. 
a Values represent mean (range). 
b Missing values were excluded in the calculation of p-values. 
c Statistically significant differences.
Table 1 - Clinical and laboratory characteristics of patients with chronic lymphocytic leukemia (CLL).
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(Y), 0.40 (H), 0.60 (L), 0.74 (A), and 0.26 (O). The X/Y, H/L, and 
A/O allele frequencies did not differ between the two groups 
(p-value = 0.39, p-value = 0.12, and p-value = 0.5, respectively). 
The genotype distributions of the polymorphisms in the group 
with infections compared to the group with no infection did 
not show any significant difference (p-value = 0.29, p-value = 
0.31, and p-value = 0.37, respectively; Table 2).
is one of the most common genetic influences on immune 
response;22 this has been associated with recurrent episodes 
of infection in several diseases, including hematological 
malignancies.23-25 Nevertheless, the results of the impact of 
MBL2 gene polymorphisms in hematological malignancies 
are controversial. Kilpatrick et al.23 found no association 
between MBL serum levels and chemotherapy-related 
infection (alone or after bone marrow transplantation) in 
patients with hematological malignancies. In agreement, 
Klostergaard et al.24 demonstrated that the occurrence of 
sepsis in patients with acute myeloid leukemia treated with 
high-dose chemotherapy was not associated with MBL2 gene 
polymorphisms. By contrast, Vekemans et al.25 observed that 
MBL protein deficiency is associated with a higher frequency 
of infections in patients with hematological malignancies 
submitted to intensive chemotherapy.
To the authors’ knowledge, the present study was the first 
to address the information regarding MBL2 polymorphisms in 
the development of infections in chronic lymphoproliferative 
disorders. Although MBL2 gene polymorphisms were not 
evaluated in healthy subjects, the present data showed 
similar allele and genotype frequencies in CLL patients as 
healthy donors from other studies.26,27 Regarding MBL2 gene 
polymorphisms in respect to occurrence of infections, it was 
not possible to demonstrate a significant association between 
polymorphisms of the -221 and -550 promoter regions and 
exon 1 of the MBL2 gene with higher risk of infection in CLL 
patients. However, due to the well-known occurrence of 
infectious events in CLL, some patients were subjected to anti-
infective prophylaxis, which could have masked the risk for 
developing infections.
The distribution of MBL2 haplotypes demonstrated a higher 
frequency of HYA and LYA haplotypes, corroborating previous 
studies,28,29 although the MBL serum levels did not show 
significant differences between groups. The heterogeneity 
of data concerning susceptibility to infection by deficiencies 
in functional MBL protein could be explained by the fact that 
some microorganisms are facultative intracellular pathogens, 
which suffer the action of the innate immune system only 
when exposed to the extracellular environment.30 Therefore, 
this mechanism could influence not only bacterial persistence, 
but also the progression of infections.
Advanced clinical stages in CLL are associated with a 
worse prognosis and, consequently, a higher occurrence of 
comorbidities.31 In the present cohort, a low frequency of 
infection was observed in patients with initial clinical stage 
The most frequent haplotypes were HYA/LYA (15%) and 
LYA/LXA (15%). The frequency of haplotypes related to high 
(HYA/HYA, HYA/LYA, LYA/LYA), intermediate (HYA/LXA, HYA/
HYO, HYA/LYO, LYA/LXA, LYA/LYO, LXA/LXA, LXA/LYO), and 
low (HYO/LYO, HYO/HYO, HYO/LXA, LYO/LYO, LYO/LXO) levels 
of functional serum MBL were 0.31, 0.62, and 0.07, respectively. 
The association between the haplotypes with the risk of 
infection was not significant (p-value = 0.208; Table 3).
Discussion
Accumulating evidence indicates that loss of function of MBL 












Genotype - n (%) 0.29
    HH 13 (11.2) 6 (8.3) 7 (15.9)
    HL 52 (44.8) 31 (43.1) 21 (47.7)
    LL 51 (44) 35 (48.6) 16 (36.4)
Allele - % 0.12
    H 33.6 29.9 39.8
    L 66.4 70.1 60.2
Promoter (-221)
Genotype - n (%) 0.31
    XX 1 (0.9) 0 (0) 1 (2.2)
    YX 39 (33.6) 23 (31.9) 16 (36.4)
    YY 76 (65.5) 49 (68.1) 27 (61.4)
Allele - % 0.39
    X 17.7 16 20.5
    Y 82.3 84 79.5
Exon 1
Genotype - n (%) 0.37
    AA 68 (58.6) 45 (62.5) 23 (52.3)
    AO 41 (35.4) 22 (30.6) 19 (43.2)
    OO 7 (6) 5 (6.9) 2 (4.5)
Allele - % 0.5
    A 76.3 77.8 73.9
    O 23.7 22.2 26.1
Table 2 - Frequencies of genotypes and alleles related 
to promoter region (-550 and -221) and exon 1 of 
MBL2 gene polymorphisms in patients with chronic 
lymphocytic leukemia (CLL).
MBL serum 










High 37 (31.9) 26 (36.1) 11 (25)
Intermediate/
low
79 (68.1) 46 (63.9) 33 (75)
Table 3 - MBL2 haplotypes correlating with mannose-
binding lectin (MBL) serum levels in patients with 
chronic lymphocytic leukemia (CLL).
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(Binet A) and a significant association between risk of infection 
and splenomegaly was observed. Additionally, the follow-up 
time was significantly lower in the group with no infection, 
which may have been influenced by the absence of infection 
in this group, due to the short time of the clinical course of 
the disease. It must be highlighted that infectious events 
occur as a time dependent variable and that the cumulative 
incidence of infection between patients with and without 
MBL2 polymorphisms would add valuable information to the 
results. However, this strategy was not explored due to the 
limited numbers of patients in the study in relation to the 
small number of deaths (n = 8).
Conclusion
In summary, the present study demonstrated that MBL2 
polymorphisms were not associated with high-risk of infection 
in CLL. However, the conclusions are limited by the sample 
size, and need to be further investigated in a larger cohort. 
Furthermore, an accurate assay of plasma MBL concentration 
would be helpful to determine the role of MBL2 polymorphisms 
in the functional protein levels and their prognostic impact 
on CLL.
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